Similar articles

• Increasing incidence and pretransplantation screening of hepatocellular carcinoma.

  Everson GT. Everson GT. Liver Transpl. 2000 Nov;6(6 Suppl 2):S2-10. doi: 10.1053/jlts.2000.1918. Liver Transpl. 2000. PMID: 11084078
• An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.

  Kemmer N, Neff G, Kaiser T, Zacharias V, Thomas M, Tevar A, Satwah S, Shukla R, Buell J. Kemmer N, et al. Liver Transpl. 2006 Oct;12(10):1519-22. doi: 10.1002/lt.20859. Liver Transpl. 2006. PMID: 17004260
• Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma?

  Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Yao FY, et al. Liver Transpl. 2011 Oct;17 Suppl 2:S109-16. doi: 10.1002/lt.22335. Liver Transpl. 2011. PMID: 21584927 Review. No abstract available.
• Management of pre-liver transplantation patients--part 1.

  Sharma P, Rakela J. Sharma P, et al. Liver Transpl. 2005 Feb;11(2):124-33. doi: 10.1002/lt.20353. Liver Transpl. 2005. PMID: 15666386 No abstract available.
• [Liver transplantation for hepatocellular carcinoma].

  Tanaka A, Tanaka K, Kaihara S, Ueda M, Uemoto S, Kiuchi T, Egawa H. Tanaka A, et al. Nihon Rinsho. 2001 Oct;59 Suppl 6:705-16. Nihon Rinsho. 2001. PMID: 11762042 Review. Japanese. No abstract available.